Ciprofloxacin dry powder for inhalation in patients with cystic fibrosis

Trial Profile

Ciprofloxacin dry powder for inhalation in patients with cystic fibrosis

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2013

At a glance

  • Drugs Ciprofloxacin (Primary)
  • Indications Cystic fibrosis; Pseudomonal infections
  • Focus Adverse reactions
  • Sponsors Bayer HealthCare Pharmaceuticals
  • Most Recent Events

    • 08 Nov 2013 New trial record
    • 18 Sep 2013 Results published in Clinical Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top